A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 medications semaglutide or liraglutide were less likely to have suicidal thoughts or attempts than those treated with behavioral interventions.

In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.

The future of the weight loss market might not revolve around GLP-1 drugs.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third decreased risk for suicidal ideation and suicide attempts compared with lifestyle intervention alone, a large international retrospective study found.

It may not sound surprising that treating obesity in adolescents and teens may have positive mental health impacts, but researchers this week reported reassuring findings about whether popular new injectable weight loss medicines carry mental health risks.

For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to a study published online Oct.